Dr Misiewicz-Krzeminska speaks with ecancer at EHA 23 about the utility of proteins expressed within the plasma cells of patients with multiple myeloma who have been treated with VRD chemotherapy as prognostic factors for disease relapse and vulnerability.

From samples collected in previous trials, she describes the expression levels of proteins including ikaros and cyclin D as highly indicative of treatment susceptibility and suitability in patients, and a potential predictive factor to the disease in case of relapse.

These findings could lead to simple screening of patients in the near future, with no barrier to availability beyond training and education in the technique.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.